9G2 — Singapore Institute of Advanced Medicine Holdings Income Statement
0.000.00%
Last trade - 00:00- SG$30.80m
- SG$80.29m
- SG$16.65m
Annual income statement for Singapore Institute of Advanced Medicine Holdings, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 12.9 | 13.8 | 16.2 | 16.6 |
| Cost of Revenue | ||||
| Gross Profit | 11.8 | 12.6 | 15 | 15.4 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 22.2 | 28.2 | 30.5 | 37.9 |
| Operating Profit | -9.31 | -14.4 | -14.3 | -21.2 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -9.39 | -14.5 | -19 | -37.4 |
| Net Income After Taxes | -9.39 | -14.5 | -19 | -37.4 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -9.35 | -12.4 | -18.1 | -37.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -9.35 | -12.4 | -18.1 | -37.4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.009 | -0.014 | -0.018 | -0.046 |